INVESTIGATION OF CROSS IMMUNITY FOLLOWING VACCINATION WITH ALLOGENIC CANCER CELL

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。我们目前正在进行肺癌临床疫苗试验，该试验使用的是基因修饰的癌细胞。这项正在进行的疫苗研究的设计旨在调查是否会发展针对用作实际疫苗的同种异体细胞系的免疫。将进行适当的分析，包括细胞毒性T淋巴细胞分析，以及细胞因子分析和肿瘤反应的临床评估。参与的主体已经提供了适当的同意。为了从存档的血液中进行其他重要的免疫学分析，我们提出了研究人员发起的组件。我们建议检查是否已经形成了对其他肺细胞系的反应。这种反应将针对在接种过程中未接种疫苗的受试者的细胞系。这些研究将对幼稚的受试者(在接种疫苗之前)和受试者在四种疫苗接种后获得的淋巴细胞和血清进行。这些组织和血清被存档和冷冻保存，预计将在体外进行研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We are currently conducting a lung cancer clinical vaccine trial which is using gene modified cancer cells. The design of this ongoing vaccine study is geared to investigate whether immunity specifically directed against the allogenic cell lines used as the actual vaccine will develop. Appropriate assays will be performed which includes cytotoxic T-lymphocyte assays, as well as cytokine assays and clinical evaluation for tumor responses. Participating subjects already have provided appropriate consents. In order to perform additional important immunological assays from archived blood, we propose and investigator initiated component. We propose to examine whether a response against other lung cell lines has developed. This response would be specifically against cell lines the subjects had not been vaccinated during the vaccination process. These studies will be performed on lymphocytes and serum obtained from naive subjects (prior to vaccination) and subjects following each of the four vaccinations. These tissues and serum are archived and cryopreserved and propsed studies will be conducted in vitro.